Organization | Criterium, Inc.

Criterium, Inc. Report issue

For profit Phase 2

Founded: Pennington NJ United States (1991)

Organization Overview

First Clinical Trial

2011

NCT01464034

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Criterium, Inc. | Criterium Inc., d.b.a. Academic GI Cancer Consortium (AGICC)

Active Ingredients

Drugs in Phase 2 Trials (21)

abemaciclib (verzenio) (1 trial)

alx148 (1 trial)

bevacizumab (avastin) (1 trial)

brigatinib (alunbrig) (1 trial)

carfilzomib (kyprolis) (2 trials)

ceritinib (zykadia) (1 trial)

cetuximab (erbitux) (1 trial)

elacestrant (ORSERDU) (1 trial)

eribulin (halaven) (1 trial)

fulvestrant (faslodex) (1 trial)

gemcitabine (gemzar) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

palbociclib (ibrance) (1 trial)

pembrolizumab (keytruda) (1 trial)

pomalidomide (pomalyst) (1 trial)

sotorasib (LUMAKRAS) (1 trial)

tepotinib (Tepmetko) (1 trial)

trastuzumab (herceptin) (1 trial)

tucatinib (Tukysa) (1 trial)

urea (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Amyloidosis (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 12
# of Trial APIs: 21